Sandoz, a Novartis division, announced today that it has entered into a global commercialization agreement with Poland-based Polpharma Biologics for a proposed natalizumab biosimilar referencing Biogen’s Tysabri. Natalizumab is a disease-modifying therapy used to treat relapsing-remitting multiple sclerosis (MS) as well as Crohn disease.
Sandoz, a Novartis division, announced today that it has entered into a global commercialization agreement with Poland-based Polpharma Biologics for a proposed natalizumab biosimilar referencing Biogen’s Tysabri.
Natalizumab is a disease-modifying therapy used to treat relapsing-remitting multiple sclerosis (MS) as well as Crohn disease. The monoclonal antibody is a selective adhesion molecule inhibitor that binds to α4-integrin. Polpharma’s proposed biosimilar is currently in phase 3 clinical development for the treatment of MS.
Pierre Bourdage, ad interim global head of biopharmaceuticals at Sandoz, said in a statement, “Patient access to advanced medicines is important for all people diagnosed with a chronic disease, but the challenges are very pronounced for MS patients. By nature, biosimilars create competition and cost savings, which are proven to make room in healthcare systems to treat more patients.” He added that, with the agreement with Polpharma, Sandoz hopes to build on its experience with small-molecules and complex generics and to provide patients with expanded access to a disease-modifying treatment that they might otherwise be unable to access.
If it its eventually approved, the biosimilar of the high-cost natalizumab could bring some welcome relief to patients with MS who bear the burden of high—and continually increasing—costs for their therapies.
Just last week, a paper in JAMA Neurology reported that, for self-administered drugs for MS that are covered under the Medicare Part D benefit, the annual cost of treatment more than quadrupled from 2006 to 2016, from a mean of $18,660 to $75,847.1 That increase resulted in a 7.2-fold increase in patient’s out-of-pocket costs. In an accompanying editorial, Daniel M. Hartung, PharmD, MPH, and Dennis Bourdette, MD, called on neurologists to be cognizant of the financial toxicity that MS therapies impart on patients, and they added that “Neurologists should be seeking to minimize the financial adverse effects of these therapies as much as they try to minimize physical adverse effects.”2
While natalizumab is an infused drug rather than a self-administered Part D drug, it too carries a substantial price tag. According to data derived from a review of MS therapies published by the Institute for Clinical and Economic Review in 2017, the brand-name natalizumab has a yearly wholesale acquisition cost of $78,214.
References
1. San-Juan-Rodriguez A, Good CB, Heyman RA, Parekh N, Shrank WH, Hernandez I. Trends in prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis in Part D [published online August 26, 2019]. JAMA Neurol. doi:10.1001/jamaneurol.2019.2711.
2. Hartung DM, Bourdette D. Addressing the rising prices of disease-modifying therapies for multiple sclerosis [published online August 26, 2019]. JAMA Neurol. doi: doi:10.1001/jamaneurol.2019.2445.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.